Nuvation Bio Inc. (NUVB-WT)

USD 0.16

(0.65%)

EBITDA Summary of Nuvation Bio Inc.

  • Nuvation Bio Inc.'s latest annual EBITDA in 2023 was -99.6 Million USD , up 22.61% from previous year.
  • Nuvation Bio Inc.'s latest quarterly EBITDA in 2024 Q2 was -45.07 Million USD , down -2194.4% from previous quarter.
  • Nuvation Bio Inc. reported an annual EBITDA of -119.53 Million USD in 2022, down -32.28% from previous year.
  • Nuvation Bio Inc. reported an annual EBITDA of -89.34 Million USD in 2021, down -122.79% from previous year.
  • Nuvation Bio Inc. reported a quarterly EBITDA of -45.07 Million USD for 2024 Q2, down -2194.4% from previous quarter.
  • Nuvation Bio Inc. reported a quarterly EBITDA of -25.71 Million USD for 2023 Q2, up 3.02% from previous quarter.

Annual EBITDA Chart of Nuvation Bio Inc. (2023 - 2018)

Historical Annual EBITDA of Nuvation Bio Inc. (2023 - 2018)

Year EBITDA EBITDA Growth
2023 -99.6 Million USD 22.61%
2022 -119.53 Million USD -32.28%
2021 -89.34 Million USD -122.79%
2020 -43.44 Million USD -36.09%
2019 -32.08 Million USD 0.0%
2018 - USD 0.0%

Peer EBITDA Comparison of Nuvation Bio Inc.

Name EBITDA EBITDA Difference
ADC Therapeutics SA -146.76 Million USD 32.135%
Alto Neuroscience, Inc. -34.56 Million USD -188.178%
Annovis Bio, Inc. -45.03 Million USD -121.161%
Biohaven Pharmaceutical Holding Company Ltd. -429.13 Million USD 76.791%
Ginkgo Bioworks Holdings, Inc. -821.29 Million USD 87.873%
Nuvation Bio Inc. -99.6 Million USD -0.0%
Arcus Biosciences, Inc. -283 Million USD 64.806%
Theriva Biologics, Inc. -19.85 Million USD -401.662%
Zymeworks Inc. -129.95 Million USD 23.359%